Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 22-25 July 2024

Human medicines European public assessment report (EPAR): Orladeyo, berotralstat, Date of authorisation: 30/04/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Velsipity, Etrasimod, Date of authorisation: 16/02/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Jeraygo, aprocitentan, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Jemperli, dostarlimab, Date of authorisation: 21/04/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): Fluad Tetra, influenza vaccine (surface antigen, inactivated, adjuvanted), Date of authorisation: 20/05/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Vazkepa, icosapent ethyl, Date of authorisation: 26/03/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Cabazitaxel Accord, cabazitaxel, Date of authorisation: 28/08/2020, Revision: 6, Status: Authorised

Twelfth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines, Online, European Medicines Agency, Amsterdam, the Netherlands, from 19 June 2024, 13:00 (CEST) to 19 June 2024, 18:00 (CEST)